280 related articles for article (PubMed ID: 22507337)
1. Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients: ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
Int J Immunopathol Pharmacol; 2012; 25(1):247-58. PubMed ID: 22507337
[TBL] [Abstract][Full Text] [Related]
2. Effects of HAART on platelet-activating factor metabolism in naive HIV-infected patients I: study of the tenofovir-DF/emtricitabine/efavirenz HAART regimen.
Chini M; Tsoupras AB; Mangafas N; Tsogas N; Papakonstantinou VD; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):766-75. PubMed ID: 22050695
[TBL] [Abstract][Full Text] [Related]
3. Anti-platelet-activating factor effects of highly active antiretroviral therapy (HAART): a new insight in the drug therapy of HIV infection?
Tsoupras AB; Chini M; Tsogas N; Fragopoulou E; Nomikos T; Lioni A; Mangafas N; Demopoulos CA; Antonopoulou S; Lazanas MC
AIDS Res Hum Retroviruses; 2008 Aug; 24(8):1079-86. PubMed ID: 18620493
[TBL] [Abstract][Full Text] [Related]
4. Recent availability of two novel, fixed formulations of antiretroviral nucleoside analogues: a 12-month prospective, open-label survey of their practical use and therapeutic perspectives in antiretroviral-naive and -experienced patients.
Manfredi R; Calza L
AIDS Patient Care STDS; 2008 Apr; 22(4):279-90. PubMed ID: 18290748
[TBL] [Abstract][Full Text] [Related]
5. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
[TBL] [Abstract][Full Text] [Related]
6. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
7. In vivo effect of two first-line ART regimens on inflammatory mediators in male HIV patients.
Papakonstantinou VD; Chini M; Mangafas N; Stamatakis GM; Tsogas N; Tsoupras AB; Psarra K; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
Lipids Health Dis; 2014 May; 13():90. PubMed ID: 24884881
[TBL] [Abstract][Full Text] [Related]
8. Rare selection of the K65R mutation in antiretroviral-naive patients failing a first-line abacavir/ lamivudine-containing HAART regimen.
Descamps D; Ait-Khaled M; Craig C; Delarue S; Damond F; Collin G; Brun-Vézinet F
Antivir Ther; 2006; 11(6):701-5. PubMed ID: 17310814
[TBL] [Abstract][Full Text] [Related]
9. Platelet-activating factor and its basic metabolic enzymes in blood of naive HIV-infected patients.
Tsoupras AB; Chini M; Mangafas N; Tsogas N; Stamatakis G; Tsantila N; Fragopoulou E; Antonopoulou S; Gargalianos P; Demopoulos CA; Lazanas MC
Angiology; 2012 Jul; 63(5):343-52. PubMed ID: 21948973
[TBL] [Abstract][Full Text] [Related]
10. A randomized study comparing a three- and four-drug HAART regimen in first-line therapy (QUAD study).
Orkin C; Stebbing J; Nelson M; Bower M; Johnson M; Mandalia S; Jones R; Moyle G; Fisher M; Gazzard B
J Antimicrob Chemother; 2005 Feb; 55(2):246-51. PubMed ID: 15608053
[TBL] [Abstract][Full Text] [Related]
11. Compact quadruple therapy with the lamivudine/zidovudine combination tablet plus abacavir and efavirenz, followed by the lamivudine/zidovudine/abacavir triple nucleoside tablet plus efavirenz in treatment-naïve HIV-infected adults.
Ruane PJ; Parenti DM; Margolis DM; Shepp DH; Babinchak TJ; Van Kempen AS; Kauf TL; Danehower SA; Yau L; Hessenthaler SM; Goodwin D; Hernandez JE;
HIV Clin Trials; 2003; 4(4):231-43. PubMed ID: 12916008
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of simplification therapy with once-daily tenofovir, lamivudine, and efavirenz in HIV-1-infected patients with undetectable plasma viral load on HAART.
Arrizabalaga J; Arazo P; Aguirrebengoa K; García-Palomo D; Chocarro A; Labarga P; Muñoz-Sánchez MJ; Echevarría S; Oteo JA; Uriz J; Letona S; Fariñas MC; Peralta G; Pinilla J; Ferrer P; Alvarez ML; Iribarren JA
HIV Clin Trials; 2007; 8(5):328-36. PubMed ID: 17956834
[TBL] [Abstract][Full Text] [Related]
13. Immunovirological outcome and HIV-1 DNA decay in a small cohort of HIV-1-infected patients deintensificated from Abacavir/Lamivudine/Dolutegravir to Lamivudine plus Dolutegravir.
Lanzafame M; Nicole S; Rizzardo S; Piacentini D; Chiesi S; Lattuada E; Diani E; Carelli M; Vento S; Gibellini D
New Microbiol; 2018 Oct; 41(4):262-267. PubMed ID: 30311623
[TBL] [Abstract][Full Text] [Related]
14. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults.
DeJesus E; Herrera G; Teofilo E; Gerstoft J; Buendia CB; Brand JD; Brothers CH; Hernandez J; Castillo SA; Bonny T; Lanier ER; Scott TR;
Clin Infect Dis; 2004 Oct; 39(7):1038-46. PubMed ID: 15472858
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of tenofovir/emtricitabine or abacavir/lamivudine in combination with efavirenz in treatment naïve HIV patients: a 5 year retrospective observational cohort study. (the TOKEN Study).
Pammi M; Arumainayagam J; Kumari B; Ahmed-Jushuf I; Carlin EM; Chandramani S; Riddell L; Ghanem M; Das S
Int J Clin Pract; 2013 Sep; 67(9):922-3. PubMed ID: 23952469
[No Abstract] [Full Text] [Related]
16. Effectiveness and safety of generic version of abacavir/lamivudine and efavirenz in treatment naïve HIV-infected patients: a nonrandomized, open-label, phase IV study in Cali-Colombia, 2011-2012.
Galindo J; Amariles P; Mueses-Marín HF; Hincapié JA; González-Avendaño S; Galindo-Orrego X
BMC Infect Dis; 2016 Oct; 16(1):532. PubMed ID: 27716093
[TBL] [Abstract][Full Text] [Related]
17. Comparative biological and clinical outcomes after a switch from a virologically unsuccessful first protease inhibitor-containing antiretroviral combination to a 3-drug regimen containing efavirenz, nevirapine, or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
Clin Infect Dis; 2007 Jan; 44(1):120-7. PubMed ID: 17143827
[TBL] [Abstract][Full Text] [Related]
18. Comparative effectiveness of continuing a virologically effective first-line boosted protease inhibitor combination or of switching to a three-drug regimen containing either efavirenz, nevirapine or abacavir.
Bommenel T; Launay O; Meynard JL; Gilquin J; Katlama C; Lascaux AS; Mahamat A; Martinez V; Pradier C; Rouveix E; Simon A; Costagliola D; Abgrall S;
J Antimicrob Chemother; 2011 Aug; 66(8):1869-77. PubMed ID: 21636583
[TBL] [Abstract][Full Text] [Related]
19. A randomized controlled trial of single-class maintenance therapy with abacavir/lamivudine/zidovudine after standard triple antiretroviral induction therapy: final 96-week results from the FREE study.
Sprenger HG; Langebeek N; Mulder PG; Ten Napel CH; Vriesendorp R; Hoepelman AI; Legrand JC; Koopmans PP; Bravenboer B; Ten Kate RW; Groeneveld P; Bierman W; van der Werf Ts; Gisolf E; Richter C
HIV Med; 2015 Feb; 16(2):122-31. PubMed ID: 25472825
[TBL] [Abstract][Full Text] [Related]
20. Atherogenic properties of LDL particles after switching from Truvada or Kivexa plus lopinavir/r to lamivudine plus lopinavir/r: OLE-MET substudy.
Saumoy M; Tiraboschi JM; Ordoñez-Llanos J; Ribera E; Domingo P; Mallolas J; Curto J; Gatell JM; Podzamczer D
HIV Clin Trials; 2017 Mar; 18(2):49-53. PubMed ID: 28081673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
